Evidence map›Paper›PMID 39446146›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Tumor agnostic ultrasmall nanoprobes for fluorescence-guided surgical resection in peritoneal metastasis.

Neetu Singh, Wenxi Xia, Esther Need, Kylee McManus, Jiemin Huang, Sixiang Shi, Shreya Goel

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Neetu SinghDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT, 84112, USA.
Wenxi XiaDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT, 84112, USA.
Esther NeedDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT, 84112, USA.
Kylee McManusCollege of Science and Honors College (Biology), University of Utah, Salt Lake City, UT, 84112, USA.
Jiemin HuangDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT, 84112, USA.
Sixiang ShiDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT, 84112, USA. sixiang.shi@utah.edu.
Shreya GoelDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT, 84112, USA. shreya.goel@utah.edu.ORCID 0000-0001-8927-8380

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
NCI NIH HHS P30 CA042014
6 · The paper itself

Abstract

purposeSurgical excision of metastases is the only curative treatment strategy in peritoneal carcinomatosis management, and the completeness of tumor resection determines the success of the surgery. Tumor-specific fluorescence-guided probes can improve the outcomes of cytoreductive surgery and thereby prognosis. This study aimed to develop and evaluate the feasibility of fluorescently labeled ultrasmall porous silica nanoparticles (UPSN) for image-guided resection of peritoneally disseminated tumors of different origins.

methodsUltrasmall fluorescent nanoprobes were synthesized and characterized for their physicochemical properties and stability. Tumor-specific uptake and biodistribution profiles were evaluated in syngeneic CT26 colorectal and KPC-689 pancreatic cancer murine models. The practicability of real-time optical UPSN-guided resection was examined in the CT26 colorectal cancer model using a surgical stereomicroscope. Quantitative measurements of tumor sensitivity and specificity were performed. Histopathological examination validated in vivo findings about tumor-specific accumulation and safety of ultrasmall fluorescent probes.

resultsAs-synthesized UPSNs were successfully surface modified with Cy5 or Cy3 dyes maintaining sub-15 nm size and near neutral charge which is beneficial for optimized in vivo pharmacokinetics. UPSN-Cy5 demonstrated high tumor-specific uptake and favorable biodistribution profiles in peritoneal metastasis models of CT26 and KPC tumors. Dye-conjugated UPSN enabled resection of microscopic lesions and achieved a higher tumor-to-background ratios in comparison to FDA-approved indocyanine green (ICG) dye in both models. Microscopic evaluation showed tumor localization and off-target safety profile of the UPSN-Cy5.

conclusionUltrasmall fluorescent probes were effective in surgical resection of peritoneal metastases with high sensitivity and specificity, thus emerging as promising tumor agnostic agents for image-guided cancer surgery.

Indexed as

Fluorescent DyesNanoparticlesPeritoneal NeoplasmsSurgery, Computer-AssistedAnimalsCell Line, TumorFluorescenceHumansMiceOptical ImagingSilicon DioxideTissue DistributionFluorescent DyesSilicon DioxideImage-guided surgeryPeritoneal malignancySilica nanoparticlesTumor agnostic nanoprobes

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.